

DG PRE vergunning/afdeling Onderzoek en Ontwikkeling

[REDACTED]

PSI CRO Belgium BV
[REDACTED]
Diestsevest 14
3000 Leuven

uw bericht van

uw kenmerk

ons kenmerk
FAGG/DGPRE/R&D/
[REDACTED]

bijlagen

datum
11.07.2025

Dossier GMO: B/BE/25/BVW3 (2023-505805-18-00): Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe Hemophilia B

Geachte [REDACTED]

Wij informeren u dat uw vergunningsaanvraag werd goedgekeurd.

De vergunning is conform het koninklijk besluit van 21 februari 2005 tot reglementering van de doelbewuste introductie in het leefmilieu evenals van het in de handel brengen van genetisch gemodificeerde organismen of van producten die er bevatten.

(http://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl&la=N&cn=2005022131&table_name=wet)

Uw vergunning wordt verleend op basis van het gunstig advies van de Adviesraad voor Bioveiligheid van 17 juni 2025, onder de voorwaarden die in de conclusie van bovengenoemd advies zijn vermeld, namelijk:

"Based on the scientific assessment of the notification made by the Belgian expert, the Biosafety Advisory Council concludes that it is unlikely that CSL222 developed to treat haemophilia B patients by means of endogenous production of FIX-Padua variant protein will have any adverse effects on human health or on the environment in the context of the intended clinical trial provided that all the foreseen safety measures are followed.

*Therefore, the Biosafety Advisory Council issues a **positive advice with the following conditions:***

– *The notifier and the investigators must strictly apply the clinical trial protocol, and all the safety instructions as described in the following documents :*

- o Latest version of the ICF*
- o Latest version of the Protocol_2023-505805-18*
- o CSL222_3004_SNIF_V2.0*

– *As committed by the notifier, the unit of time (day or week) indicated in the title of Table 15 in the IB, which summarizes the time to first shedding negativity in Study CSL220_1001, will be adjusted to align with the time unit used in the accompanying text describing the results.*

– *Any protocol amendment has to be previously approved by the Competent Authority.*

– *The notifier is responsible to verify that each study centre has qualified personnel experienced in handling infectious material and that the investigator has the required authorizations to perform the clinical trial activities inside the hospital (laboratory, pharmacy, hospital room, consultation room...) according to the*


Regional Decrees transposing Directive 2009/41/EC on Contained use of genetically modified micro-organisms.

– The Biosafety Advisory Council should be informed within two weeks when the first patient starts the treatment and the last patient receives the last treatment.

– At the latest six months after the last visit of the last patient included in the trial, the notifier must send to the competent authority at the attention of the Biosafety Advisory Council a report with details concerning the biosafety aspects of the project. This report will at least contain:

- o The total number of patients included in the trial and the number of patients included in Belgium;*
- o A summary of all adverse events marked by the investigators as probably or definitely related to the study medication;*
- o A report on the accidental releases, if any, of CSL222."*

Hoogachtend,



Frank Vandenbroucke
Vice-eersteminister en
minister van Sociale Zaken en
Volksgezondheid, belast met
Armoedebestrijding



Jean-Luc Crucke
Minister van Mobiliteit,
Klimaat en Ecologische
Transitie